Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma
- 204 Downloads
Radioimmunotherapy (RIT) for relapsed non-Hodgkin’s lymphoma is emerging as a promising treatment strategy. Myelosuppression is the dose-limiting toxicity and may be particularly problematic in patients heavily pretreated with chemotherapy. Reliable dosimetry is likely to minimise toxicity and improve treatment efficacy, and the aim of this study was to elucidate the complex problems of dosimetry of RIT by using an integrated SPECT/CT system.
As a part of a clinical trial of 131I-anti-CD20 rituximab RIT of non-Hodgkin’s lymphoma, we employed a patient-specific prospective dosimetry method utilising the whole-body effective half-life of antibody and the patient’s ideal weight to calculate the administered activity for RIT corresponding to a prescribed radiation absorbed dose of 0.75 Gy to the whole body. A novel technique of quantitation of bone marrow uptake with hybrid SPECT/CT imaging was developed to validate this methodology by using post-RIT extended imaging and data collection.
A strong, statistically significant correlation (p=0.001) between whole-body effective half-life of antibody and effective marrow half-life was demonstrated. Furthermore, it was found that bone marrow activity concentration was proportional to administered activity per unit weight, height or body surface area (p<0.001).
The results of this study show the proposed whole-body dosimetry method to be valid and clinically applicable for safe, effective RIT.
KeywordsNon-Hodgkin’s lymphoma Rituximab Radioimmunotherapy Dosimetry SPECT/CT
- 1.Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin’s lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003;18:513–24.CrossRefPubMedGoogle Scholar
- 3.Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998;39(suppl):9S–16S.Google Scholar
- 5.DeNardo SJ, DeNardo GL, Kukis D, Shen S, Kroger L, DeNardo DA, et al. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumour regression in patients with lymphoma. J Nucl Med 1999;40:303–10Google Scholar
- 11.Bouchet LG, Bolch WE, Howell RW, Rao DV. S values for radionuclides localized within the skeleton. J Nucl Med 2000;41:189–212.Google Scholar
- 15.Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from four clinical trials. J Nucl Med 2003;44:465–74.PubMedGoogle Scholar
- 16.Snyder WS et al. Report of the task group on reference man. Pergamon Press, ICRP report No.23. Oxford, UK: International Commission on Radiological Protection; 1974.Google Scholar
- 18.ICRP 70, Basic anatomical and physiological data for use in radiological protection: the skeleton. ICRP publication 70. Oxford, UK: International Commission on Radiological Protection; 1995.Google Scholar
- 19.Patton JA, Delbeke D, Sandler MP. Image fusion using an integrated, dual-head coincidence camera with X-ray tube-based attenuation maps. J Nucl Med 2000;41:1364–68.Google Scholar
- 21.Duck FA. Physical properties of tissue: a comprehensive reference book. New York: Academic Press; 1990.Google Scholar